Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Bavarian Nordic (BVNRY : OTC)

• Company Description    Bavarian Nordic A/S is a biotechnology company. It focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases. The company's product pipeline consists of IMVAMUNE(R), PROSTVAC (R), MVA-BN Brachyury, CV-301, MVA-BN Filo which are in clinical trial stage. Bavarian Nordic A/S is headquartered in Kvistgaard, Denmark. Number of Employees: 1,611

• Price / Volume Information    Yesterday's Closing Price: $9.93 Daily Weekly Monthly 20 Day Moving Average: 2,028 shares Shares Outstanding: 237.71 (millions) Market Capitalization: $2,359.51 (millions) Beta: 1.34 52 Week High: $12.85 52 Week Low: $6.60 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 0.21% 0.38% 12 Week -16.66% -18.00% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL Philip Heymans Alle 3 - Hellerup,G7 2900 DNK ph: 45-3326-8383 fax: 45-3326-8380 investor@bavarian-nordic.com http://www.bavarian-nordic.com

• General Corporate Information    Officers Paul Chaplin - Chief Executive Officer and President Anders Gersel Pedersen - Deputy Chairman Luc Debruyne - Chairman of the Board Henrik Juuel - Chief Financial Officer and Executive Vice Preside Frank Verwiel - Director Peer Information Bavarian Nordic (CORR.) Bavarian Nordic (RSPI) Bavarian Nordic (CGXP) Bavarian Nordic (BGEN) Bavarian Nordic (GTBP) Bavarian Nordic (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 071771109 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/12/26 Share - Related Items Shares Outstanding: 237.71 Most Recent Split Date: (:1) Beta: 1.34 Market Capitalization: $2,359.51 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: 0.00 Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/12/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: 6.40 PEG Ratio: - Price Ratios Price/Book: 1.14 Price/Cash Flow: 9.80 Price / Sales: 2.31 EPS Growth vs. Year Ago Period: 1,700.00% vs. Previous Quarter: 213.04% Sales Growth vs. Year Ago Period: 39.97% vs. Previous Quarter: 11.94% ROE 12/31/25 - - 09/30/25 - 20.47 06/30/25 - 12.35 ROA 12/31/25 - - 09/30/25 - 17.31 06/30/25 - 10.11 Current Ratio 12/31/25 - - 09/30/25 - 3.84 06/30/25 - 3.35 Quick Ratio 12/31/25 - - 09/30/25 - 2.43 06/30/25 - 1.74 Operating Margin 12/31/25 - - 09/30/25 - 35.96 06/30/25 - 21.95 Net Margin 12/31/25 - - 09/30/25 - 35.96 06/30/25 - 21.95 Pre-Tax Margin 12/31/25 - - 09/30/25 - 37.27 06/30/25 - 22.12 Book Value 12/31/25 - - 09/30/25 - 8.67 06/30/25 - 7.75 Inventory Turnover 12/31/25 - - 09/30/25 - 1.26 06/30/25 - 1.25 Debt-to-Equity 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - - 09/30/25 - 0.09 06/30/25 - 0.10

Powered by Zacks Investment Research ©